List of Tenants — May 1, 2003

• Bioscience Companies
• Information Technolog Companies
• Business Support Organizations

BIOSCIENCE COMPANIES (16 Total)  top

AlphaGenics
Frederic Abramson, President & CEO	P: 240-453-6242 F: 240-453-6208	Admitted: April 25, 2003 Current Employees: 4
AlphaGenics is biosceince technology company that focuses on NutriGenomics, which ties together how each person’s genes are controlled by what the person’s diet puts into his/her body. What makes NutriGenomics possible are the technology advances in biotechnology, computer and wireless communication combined with extraordinary advances in genomics.

American Laboratory Technologies - Biomedical, Inc.
Loretta Chi, President	P: 703-558-3400; 240-453-8480 F: 240-453-6208	Admitted: December 1, 2000 Current Employees: 3
A.L. Tech – Biomedical is to capitalize on its innovative, new microdissected DNA probe that will change the way clinical medicine uses DNA for diagnostic purposes.  The company will produce and sell these new, repeat sequence depleted (ReSeD) microdissected DNA probes to clinical labs, pharmaceutical companies and research laboratories.  A.L. Tech is also in the final development stage of a whole new generation of micro-dissected DNA probes for leukemia.

AnhydroCyte Corporation
Mark Berninger, CEO	P:  240-453-6285 Fax 240-631-0037	Admitted:  October 2002 Current Employees: 4
AnhydroCyte will pioneer the development of preservation technology based on biological mechanisms for desiccation tolerance, and apply this technology to the development of new products for detection of chemical or biological threat agents, biomedical research, including drug discovery, diagnostic medicine and cell based therapies.

Applied Cell Sciences
Jesse Baumgold, President & CEO	P: 240-453-6331	Admitted: January 2003
Applied Cell Sciences develops and validates drug discovery targets in the GPCR family of targets. This family is estimated to consist in about 1000 distinct proteins, of which only about 300 are known today thus leaving much work to be done.

BioMat Sciences
Ivan Stangel, DMD, President	P: 240-453-6249 F: 240-453-6208	Admitted: November 1999 Current Employees: 6
BioMat’s mission is to develop innovative materials and associated processing technologies for biomedical uses, and to translate these developments into proprietary technologies.  Technologies under development address the needs of oral health practices.

Endogeny Bio  (formerly Cell Logic)
Greg Lennon, President	P: 240-453-6316	Admitted January 2002 Current Employees: 6
Endogeny focuses on the development of factors capable to changing cells of one type into cells of another for medically beneficial reasons. Its mission is to develop small molecules and protein therapeutics that can control and regulate the transformation of cells between two distinct phenotypes. The development of such therapeutics will complement the development of stem cell therapies.

Compugen, Inc
Albine Martin, Director	P: 240-453-8485 F: 240-453-6208	Admitted: January 2001 Current Employees: 2
Compugen engages in the field of computational genomics for the study of genes and proteins using mathematics and computer science as a core competency. The company’s products are based upon its proprietary DNA clustering and assembly tools ie: LEADS 2.0, software for discovery of genes, splice variants and gene function; LabOnWeb.com, Internet computational services for life science researchers; Z3, software package for protein analysis.

Creatv MicroTech
Cha-Mei Tang, President - 240-453-6265 Pete Amstutz CFO - 301-983-2553		Admitted; August 2001 Current employees: 4
Creatv undertsakes joint research to develop an ultra-sensitive biosensor incorporating technology invented at the Naval Research Laboratory, which is interested in transferring the technology to industry. Biosensors have wide applicability in areas such as medical diagnostics, infectious diseases, environmental sensing and food contamination.

Institute for Biological Energy Alternatives (IBEA)
Hamilton Smith Scientific Director	240-453-6304 hsmith@bioenergyalts.org	Admitted May 2002 Current employees: 5

The J. Craig Venter Science Foundation
	1901 Research Boulevard 6th Floor Rockville, MD  20850 301-309-3403
Institute for Biological Energy Alternatives (IBEA) is a research-based institution dedicated to exploring solutions for carbon sequestration using microbes, microbial pathways, and plants. For example, genomics could be applied to enhance the ability of terrestrial and oceanic microbial communities to remove carbon from the atmosphere. IBEA will develop and use microbial pathways and microbial metabolism to produce fuels with higher energy content in an environmentally sound fashion. IBEA will undertake genome engineering to better understand the evolution of cellular life and how these cell components function together in a living system. IBEA has applied for 501 (c) (3) status.

ProCell
Yvonne Rosenberg, President & CSO	240-453-6247	Admitted:  April 2003 Current employees: 3
ProCell Corporation, was founded in 2000 to develop and commercialize discoveries made for the pre- and post-exposure treatment for nerve agent exposure and the treatment, diagnosis, and control of global infectious diseases of which HIV is the initial target.

Protiveris, Inc
Rob Menzi, CEO	P: 301-738-7800 F: 301-738-7800	Admitted: February 2000 Current Employees: 12
Protiveris focuses on the development of advanced microchip arrays for the emerging field of proteomics, pharmacogenomics, as well as the development of individual sensors or sensor arrays for medical or clinical applications, environmental monitoring, food safety and defense applications.  Protiveris’ near term goal is to become the worldwide leader in advanced biosensor technologies.

Quanta Biosciences
R. K. Mason, President,	P: 240-453-6344 F: 240-453-6208	Admitted: July 2001 Currrent employees: 2
Quanta Biosciences is a biotechnology company that develops and manufactures quantitative tools and technologies for the genomics/functional genomics, microarray and proteomics markets. The initial focus will be development of innovative products and technologies for quantitative analysis of gene expression, SNPs, and microarray-based methodologies.

Rexahn
Chang H. Ahn, Ph.D. President	P: 240-453-6230;  6337 F: 240-453-6208	Admitted May 2001 Current employees: 6
Rexahn is engaged in the discovery and development of breakthrough drugs or therapeutics. It seeks to produce validated drug targets and drug leads, and develop new proprietary drags that address major unmet medical needs. The Company’s research programs, all of which address attractive commercial markets, include cancer, hepatitis, obesity and lipid disorders and a class of drug targets involved in signaling mechanisms such as orphan receptors and protein kinases. Rexahn focuses first on Antisense gene therapies.

Synergy America, Inc.
Don Chen, President & CEO	P: 301-453-8475 F: 301-315-8868	Admitted: November, 2000 Current Employees: 7
Synergy America (SynAm) is a biopharmaceutical company. Its mission is three-fold: (1) a short term goal to develop cost-effective approaches to provide low cost, safe and effective patent-expired biopharmaceuticals for treatments of devastating diseases; (2) a mid-term goal to provide dietary supplements from traditional Chinese herbal medicine; and (3) a relatively low risk long term goal to develop broadly effective vaccine, either as a conjugate vaccine or a DNA-vaccine, for prevention of diseases or for passive immunization.

TransMedix
Steve Huang, President	P: 240-453-6347	Admitted April 2003 Current employees: 4
TransMedix Corporation’s vision is to become a leader in procuring homogeneous mRNA and protein expression profiles for cells of particular diseases to research, diagnostic, and pharmaceutical communities worldwide.  The Company also plans to leverage its proprietary microdissection technology to further drug discovery and become a key player in the functional genomic arena.  In the drug target area, TransMedix’s primary focus will be in the area of cancer disease cells.

20/20 GeneSystems
John Cohen, President & CEO	P: 240-453-6343	Admitted: September 2001 Current Employees:  7
20/20 GeneSystems develops proprietary tools for identifying large numbers of proteins in biological samples that would facilitate biomedical research and laboratory medicine. It is licensing technologies from NIH. Users of the company’s technology can compare the protein expression patterns between normal and diseased tissue, or between drug treated and untreated cells, to quickly and easily (i) identify or validate drug targets, (ii) screen therapeutic compounds, and (iii) create molecular profiles to predict patient outcome and response to therapy.

IT COMPANIES (10 Total)  top

BUSINESS SUPPORT ORGANIZATIONS  top